Denali Therapeutics Inc.
Symbool: DNLI
NASDAQ
20.86
USDMarktprijs vandaag
-14.6980
Koers/Winst Verhouding
-0.2609
Koers/Winst Groei Verhouding
2.88B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Denali Therapeutics Inc. (DNLI) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4623.21 | 1034.5 | 1336.2 | 865.4 | |||||||||
balance-sheet.row.short-term-investments | 4147.99 | 907.4 | 1118.2 | 571.9 | |||||||||
balance-sheet.row.net-receivables | 9.3 | 2.7 | 5 | 1.2 | |||||||||
balance-sheet.row.inventory | -6.6 | 0 | -5 | 0 | |||||||||
balance-sheet.row.other-current-assets | 130.34 | 26.9 | 36.1 | 30.6 | |||||||||
balance-sheet.row.total-current-assets | 4756.24 | 1064.1 | 1372.3 | 897.2 | |||||||||
balance-sheet.row.property-plant-equipment-net | 283.89 | 71.6 | 74.5 | 69.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 12.61 | 1.6 | 1.5 | 425.4 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 53.03 | 16.5 | 11.9 | 11.9 | |||||||||
balance-sheet.row.total-non-current-assets | 349.53 | 89.8 | 87.9 | 506.9 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.account-payables | 21.4 | 9.5 | 2.8 | 4.8 | |||||||||
balance-sheet.row.short-term-debt | 27.59 | 7.3 | 7.3 | 5.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 191.16 | 45 | 53 | 58.6 | |||||||||
Deferred Revenue Non Current | 1.05 | 0 | 0.5 | 4.7 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 270.01 | 61.2 | 63.8 | 47.7 | |||||||||
balance-sheet.row.total-non-current-liabilities | 193.36 | 45 | 53.9 | 63.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 211.49 | 45 | 60.4 | 58.6 | |||||||||
balance-sheet.row.total-liab | 802.96 | 123 | 417.8 | 441.9 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 6.81 | 1.7 | 1.7 | 1.5 | |||||||||
balance-sheet.row.retained-earnings | -4091.1 | -1116.2 | -971 | -645 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -3.97 | 0.6 | -6.9 | -2.5 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 8391.07 | 2144.8 | 2018.6 | 1608.2 | |||||||||
balance-sheet.row.total-stockholders-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5105.77 | - | - | - | |||||||||
Total Investments | 4157.49 | 909 | 1118.2 | 997.4 | |||||||||
balance-sheet.row.total-debt | 218.75 | 52.2 | 60.4 | 58.6 | |||||||||
balance-sheet.row.net-debt | -256.47 | -74.9 | -157.7 | -234.9 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -145.22 | -145.2 | -326 | -290.6 | |||||||||
cash-flows.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
cash-flows.row.deferred-income-tax | -56.28 | -2.4 | 0 | 8.7 | |||||||||
cash-flows.row.stock-based-compensation | 108.1 | 108.1 | 99.8 | 85.2 | |||||||||
cash-flows.row.change-in-working-capital | -289.93 | -289.9 | -24 | -20.4 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.account-payables | 2.43 | 2.4 | 2.3 | 3.7 | |||||||||
cash-flows.row.other-working-capital | -292.36 | -292.4 | -26.3 | -24.1 | |||||||||
cash-flows.row.other-non-cash-items | 8.61 | -45.2 | -4.9 | -3 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -357.99 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.acquisitions-net | -262.25 | 0 | 123.6 | 13.1 | |||||||||
cash-flows.row.purchases-of-investments | -1813.7 | -1813.7 | -1115 | -1422.9 | |||||||||
cash-flows.row.sales-maturities-of-investments | 2075.95 | 2075.9 | 991.5 | 1409.8 | |||||||||
cash-flows.row.other-investing-activites | 262.25 | 0 | -123.6 | -13.1 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 249.31 | 249.3 | -141.4 | -21.6 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -3.1 | -3.7 | |||||||||
cash-flows.row.common-stock-issued | 17.82 | 17.8 | 296.2 | 19.3 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | 17.82 | 17.8 | 17.6 | 3.7 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 17.82 | 17.8 | 310.7 | 19.3 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -90.86 | -90.9 | -75.4 | -213.7 | |||||||||
cash-flows.row.cash-at-end-of-period | 479.87 | 127.1 | 219.5 | 295 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 570.73 | 218 | 295 | 508.6 | |||||||||
cash-flows.row.operating-cash-flow | -357.99 | -358 | -244.7 | -211.4 | |||||||||
cash-flows.row.capital-expenditure | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.free-cash-flow | -370.93 | -370.9 | -262.5 | -219.9 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 330.53 | 330.5 | 108.5 | 48.7 | |||||||||
income-statement-row.row.cost-of-revenue | 14.92 | 16.7 | 7 | 5.6 | |||||||||
income-statement-row.row.gross-profit | 315.61 | 313.8 | 101.4 | 43.1 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 423.88 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 103.35 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.operating-expenses | 525.05 | 510.5 | 449.2 | 344.4 | |||||||||
income-statement-row.row.cost-and-expenses | 527.23 | 527.2 | 449.2 | 344.4 | |||||||||
income-statement-row.row.interest-income | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
income-statement-row.row.ebitda-caps | -192.31 | - | - | - | |||||||||
income-statement-row.row.operating-income | -196.7 | -196.7 | -340.7 | -295.8 | |||||||||
income-statement-row.row.income-before-tax | -145.19 | -145.2 | -326 | -291.2 | |||||||||
income-statement-row.row.income-tax-expense | -12.3 | 0 | 0 | -0.6 | |||||||||
income-statement-row.row.net-income | -145.22 | -145.2 | -326 | -290.6 |
Vaak gestelde vragen
Wat is Denali Therapeutics Inc. (DNLI) totale activa?
Denali Therapeutics Inc. (DNLI) totale activa is 1153917000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 1267000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.955.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.439.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.595.
Wat is Denali Therapeutics Inc. (DNLI) nettowinst (netto-inkomen)?
De nettowinst is -145224000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 52241000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 510504000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 127106000.000.